Journal
RENAISSANCE OF CANCER IMMUNOTHERAPY
Volume 1284, Issue -, Pages 31-45Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12125
Keywords
dendritic cells; immunotherapy; cancer; vaccine
Categories
Ask authors/readers for more resources
The U. S. Food and Drug Administration's approval of the first cell-based immunotherapy has rejuvenated interest in the field. Early clinical trials have established the ability of dendritic cell (DC) immunotherapy to exploit a patient's own immune system to induce antitum or immune responses. However, suboptimal conditions for generating potent immunostimulatory DCs, in addition to the suppression mediated by the tumor microenvironment, have contributed to limited clinical success in vivo. Therefore, combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be key to achieving effective, durable, antitumor immune responses that translate to better clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available